Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 9th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
NeuroVoices: Joseph Foss, MD, on NTRX-07 and CBR2-Targeting Therapies for Alzheimer Disease
November 8th 2023The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.
Social Determinants of Health Lead to Greater Suboptimal Treatment Response in Myasthenia Gravis
November 2nd 2023A retrospective study presented at the 2023 AANEM meeting revealed that social determinants of health are linked to poorer treatment outcomes in myasthenia gravis patients, emphasizing the need for identifying and supporting at-risk individuals.
NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease
November 1st 2023David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.
Combination of Aducanumab Infusion and Focused Ultrasound Accelerates Reduction of Amyloid-ß Plaques
October 27th 2023The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.
Dihydroergotamine Safe in Chronic Migraine With Cardiovascular Risk
October 24th 2023Stratification of the cohort into low- and elevated-cardiovascular risk groups revealed no differences in cardiovascular adverse events with repetitive DHE; however, elevated-risk patients had higher mean arterial blood pressure.